We are live on ! Find out more
PA

Perceptive Advisors Portfolio holdings

AUM $6.66B
1-Year Est. Return 360.84%
This Fund
S&P 500
This Quarter Est. Return
+27.17%
1 Year Est. Return
+360.84%
3 Year Est. Return
+1,707.27%
5 Year Est. Return
+3,210.42%
10 Year Est. Return
+53,055.89%
AUM
$1.66B
AUM Growth
+$374M
Cap. Flow
+$115M
Cap. Flow %
6.95%
Top 10 Hldgs %
47.85%
Holding
212
New
55
Increased
41
Reduced
36
Closed
38

Top Buys

Rank Stock Value
1
RXDX
Ignyta, Inc.
RXDX
+$23.8M
2
VTRS icon
Viatris
VTRS
+$14.8M
3
EGRX
Eagle Pharmaceuticals, Inc.
EGRX
+$14.4M
4
SRPT icon
Sarepta Therapeutics
SRPT
+$12.4M
5
NVRO
NEVRO CORP.
NVRO
+$12.3M

Top Sells

Rank Stock Value
1
NBIX icon
Neurocrine Biosciences
NBIX
+$19.4M
2
BLUE
bluebird bio
BLUE
+$16.3M
3
BLCM
Bellicum Pharmaceuticals, Inc.
BLCM
+$12.1M
4
QURE icon
uniQure
QURE
+$11.1M
5
RLYP
RELYPSA INC COM
RLYP
+$10.8M

Sector Composition

Rank Sector Weight
1 Healthcare 81.96%
2 Consumer Staples 0.52%
3 Financials 0.09%
4 Technology 0.06%
5 Consumer Discretionary 0.05%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
CI icon
76
Cigna
CI
$73.8B
$3.56M 0.21%
21,970
+20,000
+1,015% +$2.76M
CPRX
77
DELISTED
Catalyst Pharmaceutical
CPRX
$3.52M 0.21%
851,200
-348,800
-29% -$1.39M
TVTX icon
78
PUT
Travere Therapeutics
TVTX
$6.32B
$3.31M 0.2%
+100,000
New +$2.74M
SSO icon
79
PUT
ProShares Ultra S&P500
SSO
$8.41B
$3.23M 0.19%
+400,000
New +$3.35M
NDRM
80
DELISTED
NeuroDerm Ltd. Ordinary Shares
NDRM
$3.07M 0.18%
200,000
-150,000
-43% -$2.11M
EVH icon
81
Evolent Health
EVH
$553M
$2.98M 0.18%
+152,800
New +$2.85M
WBA
82
DELISTED
Walgreens Boots Alliance
WBA
$2.98M 0.18%
35,292
+15,000
+74% +$1.29M
MGNX icon
83
MacroGenics
MGNX
$266M
$2.89M 0.17%
76,208
-30,000
-28% -$986K
GNMX
84
DELISTED
Aevi Genomic Medicine Inc
GNMX
$2.85M 0.17%
465,225
-174,000
-27% -$1.35M
IMMU
85
PUT
DELISTED
Immunomedics Inc
IMMU
$2.84M 0.17%
700,000
+100,000
+17% +$409K
CRBP icon
86
Corbus Pharmaceuticals
CRBP
$219M
$2.68M 0.16%
+29,000
New +$2.92M
DERM
87
DELISTED
Dermira, Inc.
DERM
$2.67M 0.16%
152,000
– –
XENE icon
88
Xenon Pharmaceuticals
XENE
$5.85B
$2.59M 0.16%
225,000
– –
IMMU
89
DELISTED
Immunomedics Inc
IMMU
$2.44M 0.15%
+600,000
New +$2.45M
ABEO icon
90
Abeona Therapeutics
ABEO
$355M
$2.38M 0.14%
18,800
-31,200
-62% -$4.69M
NVTA
91
DELISTED
Invitae Corporation
NVTA
$2.31M 0.14%
299,583
+134,583
+82% +$1.91M
HEWG
92
DELISTED
iShares Currency Hedged MSCI Germany ETF
HEWG
$2.27M 0.14%
87,000
+2,000
+2% +$55.2K
UUP icon
93
Invesco DB US Dollar Index Bullish Fund
UUP
$321M
$2.25M 0.14%
+90,000
New +$2.27M
ABEOW
94
DELISTED
Abeona Therapeutics Inc Warrant
ABEOW
$2.25M 0.14%
+1,250,000
New +$2.79M
RGLS
95
PUT
DELISTED
Regulus Therapeutics
RGLS
$2.2M 0.13%
+1,667
New +$2.69M
VTAE
96
DELISTED
VITAE PHARMACEUTICALS INC COMMON STOCK
VTAE
$2.16M 0.13%
+150,000
New +$2.04M
VIRX
97
DELISTED
Viracta Therapeutics, Inc. Common Stock
VIRX
$2.11M 0.13%
3,333
– –
MCRB icon
98
Seres Therapeutics
MCRB
$50.2M
$2.08M 0.13%
+2,500
New +$2.18M
SSO icon
99
ProShares Ultra S&P500
SSO
$8.41B
$1.94M 0.12%
+240,000
New +$2.01M
VCEL icon
100
Vericel Corp
VCEL
$2.21B
$1.89M 0.11%
528,697
-60,600
-10% -$208K
2 3
4
5 6

Similar funds

QP
Quilter Plc London, United Kingdom $6.65B AUM 37.83% 1-Year Est. Return
FCBT
First Citizens Bank & Trust Raleigh, North Carolina $6.69B AUM 24.48% 1-Year Est. Return
RWM
Ritholtz Wealth Management New York $6.7B AUM 32.7% 1-Year Est. Return
AWA
Arkadios Wealth Advisors Atlanta, Georgia $6.6B AUM 30.67% 1-Year Est. Return
WHRC
W.H. Reaves & Co Jersey City, New Jersey $6.59B AUM 31.9% 1-Year Est. Return
LSERS
Louisiana State Employees Retirement System Baton Rouge, Louisiana $6.74B AUM 53.06% 1-Year Est. Return
CAG
Crestwood Advisors Group Boston, Massachusetts $6.74B AUM 30.22% 1-Year Est. Return
MCM
Moore Capital Management New York $6.74B AUM 45.87% 1-Year Est. Return

Perceptive Advisors's Q2 2015 Portfolio in Review

As of Q2 2015, Perceptive Advisors held 212 positions worth $1.66B, up 29% from $1.29B the previous quarter. Its ten largest holdings account for 48% of the portfolio.

Perceptive Advisors deployed $115M of net new capital in Q2 2015, opening 55 new positions and adding to 41 existing holdings. Its largest new stake was Ignyta, Inc.: 1,967,600 shares worth $29.7M.

By sector, the portfolio is most concentrated in Healthcare at 82% of assets, down from 84% a quarter earlier, followed by Consumer Staples and Financials.

On the sell side, the largest reduction was Neurocrine Biosciences, an estimated $19.4M trimmed.

  • Perceptive Advisors's largest Q2 2015 buy was Ignyta, Inc.: 1,967,600 shares worth $29.7M.
  • Perceptive Advisors added most to Viatris in Q2 2015, an estimated $14.8M increase.
  • Perceptive Advisors's biggest Q2 2015 reduction was Neurocrine Biosciences, cutting an estimated $19.4M.
  • Perceptive Advisors fully exited bluebird bio in Q2 2015, selling an estimated $16.3M.
  • Perceptive Advisors's ten largest holdings make up 48% of its $1.66B portfolio in Q2 2015.
  • Perceptive Advisors opened 55 new positions and closed 38 in Q2 2015.
  • Perceptive Advisors's portfolio value rose 29% quarter-over-quarter to $1.66B.

Based on Perceptive Advisors's 13F filing for Q2 2015, filed 14 Aug 2015.